3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Adenomatous Polyposis Coli
2
Pathologic Complete Response
1
Pancreatic Intraductal Neoplasms
1
Pain
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hypertension
1
Coproporphyria
1
Aberrant Crypt Foci
1
Interventions
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Carboplatin
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn